AZR Azora Therapeutics, Inc. (DE)
Pharmaceutical Preparations · Nasdaq · SEC CIK 1513525 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,397.4%
TTM EPS YoY76.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-855.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets22.4%
Debt / equity—
Current ratio4.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.13x
Accruals ratio-742.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.77M | $440,000 | $432,530 | $619,396 | $521,000 | $732,000 | $746,891 | $730,793 |
| SG&A expense | $5.76M | $5.40M | $1.57M | $1.27M | $1.24M | $1.15M | $1.52M | $1.21M |
| Operating income | -$7.53M | -$52.02M | -$2.00M | -$1.89M | -$1.76M | -$1.88M | -$2.27M | -$1.94M |
| Pretax income | — | — | — | — | — | — | — | -$2.07M |
| Net income | -$64.56M | -$51.99M | -$2.02M | -$2.00M | -$1.79M | -$1.96M | -$2.23M | -$2.07M |
| EPS (basic) | -4.52 | -11.25 | -1.48 | — | -2.02 | -4.61 | -8.52 | — |
| EPS (diluted) | -4.52 | -11.25 | -1.48 | — | -2.02 | -4.61 | -8.52 | — |
| Weighted avg. shares (diluted) | 14.30M | 4.62M | 1.37M | — | 886,852 | 424,908 | 261,590 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $22.00M | $28.71M | $4.58M | $5.88M | $4.61M | $5.92M | $2.37M | $3.75M |
| Current assets | $22.38M | $28.84M | $4.80M | $6.18M | $5.01M | $6.08M | $2.63M | $4.06M |
| Intangibles | $3,000 | $3,000 | $2,643 | $3,000 | $2,925 | $3,066 | $3,207 | $3,348 |
| Total assets | $22.53M | $29.09M | $5.23M | $6.67M | $5.66M | $6.80M | $3.45M | $5.04M |
| Current liabilities | $5.06M | $5.12M | $1.51M | $1.40M | $1.15M | $1.21M | $1.32M | $975,858 |
| Total liabilities | $5.06M | $28.93M | $1.51M | $1.40M | $1.15M | $1.21M | $1.32M | $975,858 |
| Shareholders' equity | -$21.06M | -$38.38M | $3.72M | $5.28M | $4.50M | $5.59M | $2.13M | $4.07M |
| Shares outstanding | 2.63M | 2.63M | 1.51M | 1.11M | 23.84M | 21.53M | 6.65M | 258,826 |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.63M | -$6.36M | -$1.61M | -$1.32M | -$1.83M | -$1.75M | -$1.59M | -$1.45M |
| Investing cash flow | $0 | — | — | $0 | $0 | $0 | $150,000 | — |
| Financing cash flow | -$35,000 | $25.21M | $315,284 | $2.60M | $525,000 | $5.30M | $50,648 | $0 |
| Stock-based compensation | $958,000 | $137,000 | $147,900 | $168,036 | $147,000 | $124,000 | $236,731 | $180,202 |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.